Daphne Karydas's most recent trade in Mineralys Therapeutics Inc was a trade of 3,000 Common Stock done at an average price of $25 . Disclosure was reported to the exchange on June 17, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Mineralys Therapeutics Inc | Daphne Karydas | Director | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 17 Jun 2026 | 3,000 | 6,200 | - | 25 | 75,000 | Common Stock |
| Mineralys Therapeutics Inc | Daphne Karydas | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.02 per share. | 17 Jun 2026 | 3,000 | 9,200 | - | 12.0 | 36,060 | Common Stock |
| Mineralys Therapeutics Inc | Daphne Karydas | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jun 2026 | 3,000 | 38,000 | - | - | Stock Option | |
| Compass Pathways PLC (ADR) | Daphne Karydas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2026 | 21,110 | 21,110 | - | - | Share Option (Right to Buy) | |
| Mineralys Therapeutics Inc | Daphne Karydas | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.02 per share. | 31 Mar 2026 | 3,000 | 9,200 | - | 12.0 | 36,060 | Common Stock |
| Mineralys Therapeutics Inc | Daphne Karydas | Director | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 31 Mar 2026 | 3,000 | 6,200 | - | 25 | 75,000 | Common Stock |
| Mineralys Therapeutics Inc | Daphne Karydas | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2026 | 3,000 | 41,000 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | Daphne Karydas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2026 | 8,300 | 8,300 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | Daphne Karydas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2026 | 6,200 | 6,200 | - | 0 | Common Stock | |
| Mineralys Therapeutics Inc | Daphne Karydas | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.20 per share. | 13 Nov 2025 | 15,000 | 15,000 | - | 10.2 | 153,000 | Common Stock |
| Mineralys Therapeutics Inc | Daphne Karydas | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 15,000 | 17,900 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | Daphne Karydas | Director | Sale of securities on an exchange or to another person at price $ 45.81 per share. | 13 Nov 2025 | 10,115 | 4,885 | - | 45.8 | 463,351 | Common Stock |
| Mineralys Therapeutics Inc | Daphne Karydas | Director | Sale of securities on an exchange or to another person at price $ 46.36 per share. | 13 Nov 2025 | 4,885 | 0 | - | 46.4 | 226,446 | Common Stock |
| Compass Pathways PLC (ADR) | Daphne Karydas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 26,000 | 26,000 | - | - | Share Option (Right to Buy) | |
| Mineralys Therapeutics Inc | Daphne Karydas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 32,900 | 32,900 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | Daphne Karydas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2024 | 22,000 | 22,000 | - | - | Stock Option | |
| Compass Pathways PLC (ADR) | Daphne Karydas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2024 | 26,000 | 26,000 | - | - | Share Option (Right to Buy) |